维立志博-B(09887)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09887 维立志博-B

已收盘 05-18 16:08:29

62.350

-1.100

-1.73%

最高64.450	最低60.150	成交量90.94万
今开63.450	昨收63.450	日振幅6.78%
总市值124.08亿	流通市值95.40亿	总股本1.99亿
成交额5,577万	换手率0.59%	流通股本1.53亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"维立志博-B","latestPrice":62.35,"timestamp":1779091709010,"preClose":63.45,"halted":0,"volume":909447,"delay":0,"changeRate":-0.017336485421591826,"floatShares":153000000,"shares":199000000,"eps":-1.3933761158966325,"marketStatus":"已收盘","change":-1.1,"latestTime":"05-18 16:08:29","open":63.45,"high":64.45,"low":60.15,"amount":55768888,"amplitude":0.06777,"askPrice":62.9,"askSize":100,"bidPrice":62.35,"bidSize":800,"shortable":3,"etf":0,"ttmEps":-1.3553749490994516,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779154200000},"marketStatusCode":5,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":63.45,"openAndCloseTimeList":[[1779067800000,1779076800000],[1779080400000,1779091200000]],"volumeRatio":0.872167,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09887/tweets","defaultTab":"tweets","newsList":[{"id":"1178121731","title":"一周港股牛熊榜 |  金辉控股飙152%领跑，京西国际、天岳先进升逾六成强势爆发","url":"https://stock-news.laohu8.com/highlight/detail?id=1178121731","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178121731?lang=zh_cn&edition=full","pubTime":"2026-05-15 17:43","pubTimestamp":1778838189,"startTime":"0","endTime":"0","summary":"今日股价显著放量，收盘升205%，成交额超10亿港元。京西国际于5月10日晚间发布公告，披露控股股东京西智行集团告知，其与立讯精密订立买卖协议，立讯精密将收购京西智行集团全部股权，从而间接持有京西国际约59.50%股份，有望成为其最终控股股东。次日股价再升约13.60%，两个交易日累计升逾60%。受金价回软拖累，港股黄金股板块普遍走弱，灵宝黄金本周跌幅逾20%，领跌黄金板块。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b8ee1f948934007dbda4ac7ad69286fb","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02339","02631","02658","09887","01236","09993","09900","00068","03330","00326"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2635076837","title":"维立志博-B(09887)：吴凤岚获委任为非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2635076837","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635076837?lang=zh_cn&edition=full","pubTime":"2026-05-15 17:16","pubTimestamp":1778836605,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)发布公告，吴凤岚博士已获委任为公司非执行董事，自2026年5月15日起生效及至第一届董事会任期届满为止，且根据公司的章程，吴博士合资格在其任期届满后于股东会上重选连任。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442264.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252160.HKD","HK0000252152.HKD","BK1161","HK0000500386.USD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635748331","title":"维立志博-B(09887)就H股全流通获联交所授出上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2635748331","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635748331?lang=zh_cn&edition=full","pubTime":"2026-05-14 21:10","pubTimestamp":1778764220,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)公布，公司已收到联交所于2026年5月14日所授出约4439.16万股H股上市及买卖的批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441926.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252160.HKD","BK1161","HK0000252152.HKD","09887","IPOS","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633245610","title":"维立志博-B(09887)：中国证监会就H股全流通出具备案通知书及公司拟实施H股全流通计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2633245610","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633245610?lang=zh_cn&edition=full","pubTime":"2026-05-08 20:23","pubTimestamp":1778243033,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，公司已代表23名公司股东向中国证监会提交申请，有关23名股东所持合共4439.16万股未上市股份转换为H股。于2026年5月7日，公司收到中国证监会就H股全流通出具日期为2026年4月27日的《关于南京维立志博生物科技股份有限公司未上市股份“全流通”备案通知书》。根据备案通知书，若公司自备案通知书出具之日起12个月内未完成转换及上市，如拟继续推进，应当更新备案材料。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439753.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维立志博-B(09887)：中国证监会就H股全流通出具备案通知书及公司拟实施H股全流通计划","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252152.HKD","09887","HK0000500386.USD","HK0000252160.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633480440","title":"港股异动 | 维立志博-B(09887)尾盘涨近3% Dianthus正推进LBL-047临床开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2633480440","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633480440?lang=zh_cn&edition=full","pubTime":"2026-05-08 15:25","pubTimestamp":1778225156,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维立志博-B尾盘涨近3%，截至发稿，涨2.65%，报81.3港元，成交额4950.42万港元。作为战略重点的核心管线资产，Dianthus正在推进LBL-047的临床开发，以验证其在SjD、SLE和DM三项存在高度未满足需求适应症中的临床价值。于2026年3月，Dianthus成功完成一轮扩大规模的包销公开发行，募集资金总额约7.19亿美元，为推进LBL-047的全球开发提供了坚实的资本保障。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439488.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK1161","HK0000500386.USD","09887","VXUS","HK0000252152.HKD","HK0000252160.HKD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197737270","title":"维立志博-B4月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1197737270","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197737270?lang=zh_cn&edition=full","pubTime":"2026-05-06 16:38","pubTimestamp":1778056698,"startTime":"0","endTime":"0","summary":"南京维立志博生物科技有限公司于2026年5月6日发布2026年4月股份变动月报表。公告显示，截至2026年4月30日，公司股本结构保持稳定，未有新增发行、购回或注销股份活动。本期已发行股份总数与上期持平，H股与其他未上市普通股数目均无变化，分别维持在153,278,691股和45,613,109股。截至本月底，维立志博-B的已发行股份总数仍保持在198,891,800股，符合香港联交所《上市规则》及相关法律法规的要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633976162","title":"维立志博-B(09887)：LBL-047优先开发干燥综合征、系统性红斑狼疮和皮肌炎临床适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2633976162","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633976162?lang=zh_cn&edition=full","pubTime":"2026-05-06 08:40","pubTimestamp":1778028013,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，其合作伙伴Dianthus Therapeutics已选定干燥综合征、系统性红斑狼疮和皮肌炎作为LBL-047临床开发的首批三项优先适应症。作为战略重点的核心管线资产，Dianthus正在推进LBL-047的临床开发，以验证其在SjD、SLE和DM三项存在高度未满足需求适应症中的临床价值。于2025年10月16日，本公司与Dianthus达成独家全球合作伙伴关系，交易总金额最高可达10亿美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438295.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维立志博-B(09887)：LBL-047优先开发干燥综合征、系统性红斑狼疮和皮肌炎临床适应症","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252152.HKD","09887","HK0000500386.USD","HK0000252160.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630635700","title":"港股异动 | 维立志博-B(09887)午后涨超4% 核心产品LBL-024上市在即 展现重磅单品潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2630635700","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630635700?lang=zh_cn&edition=full","pubTime":"2026-04-27 14:52","pubTimestamp":1777272738,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维立志博-B午后涨超4%，截至发稿，涨2.28%，报85.3港元，成交额3735.49万港元。消息面上，维立志博近日宣布，公司自主研发的PD-L1/4-1BB双特异性抗体维利信联合用药一线治疗局部晚期或转移性胃或胃食管结合部腺癌的Ⅱ期临床研究顺利完成首例患者入组。兴业证券则表示，LBL-024 上市在即展现重磅单品潜力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434297.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","VXUS","09887","BK4588","HK0000252152.HKD","BK1161","HK0000500386.USD","HK0000252160.HKD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113586825","title":"维立志博-B（09887）2025年收入达1.77亿元 研发与管线布局加速推进","url":"https://stock-news.laohu8.com/highlight/detail?id=1113586825","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113586825?lang=zh_cn&edition=full","pubTime":"2026-04-24 21:55","pubTimestamp":1777038930,"startTime":"0","endTime":"0","summary":"维立志博-B在2025年度实现收入人民币1.77亿元，较此前尚无收入的阶段取得重大突破。报告期内，公司年内亏损收窄至人民币2.11亿元，较2024年的3.01亿元下降约29.8%。管理层将收入增长主要归因于与Dianthus Therapeutics就LBL-047订立的许可协议及后续里程碑款项，而亏损收窄则得益于收入贡献提升及股权回购义务终止后产生的公允价值损失不再确认等因素。同期行政开支约为人民币0.83亿元，较上年度略有减少，主要系部分股份支付费用在前期集中确认。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维立志博-B（09887）2025年收入达1.77亿元 研发与管线布局加速推进","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179759333","title":"维立志博-B授予董事股份购回授权，规模达已发行H股一成","url":"https://stock-news.laohu8.com/highlight/detail?id=1179759333","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179759333?lang=zh_cn&edition=full","pubTime":"2026-04-24 21:52","pubTimestamp":1777038730,"startTime":"0","endTime":"0","summary":"维立志博-B在最新公告中披露，已向董事会授予一般性股份购回授权，允许于香港联合交易所购回不超过公司已发行H股总数10%的股份。公司现有已发行股份约1.99亿股，其中H股约1.53亿股，授权规模对应最多可购回约1532.79万股H股。公司将就上述购回授权提交2026年5月15日举行的股东大会进行表决，并将于5月12日至5月15日暂停办理H股过户手续。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维立志博-B授予董事股份购回授权，规模达已发行H股一成","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138538734","title":"维立志博PD-L1/4-1BB双抗Opamtistomig（LBL-024）胃癌II期试验启动首例患者给药，开创免疫治疗联合策略新篇章","url":"https://stock-news.laohu8.com/highlight/detail?id=1138538734","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138538734?lang=zh_cn&edition=full","pubTime":"2026-04-21 21:48","pubTimestamp":1776779309,"startTime":"0","endTime":"0","summary":"维立志博研发的PD-L1/4-1BB双特异性抗体Opamtistomig正式进入II期临床试验阶段，已完成首例胃癌患者给药。这一里程碑事件标志着该创新药物在肿瘤免疫治疗领域迈出关键一步，为探索增强型免疫联合疗法开辟了新路径。作为具有双重作用机制的双抗药物，Opamtistomig通过同时靶向PD-L1和4-1BB信号通路，既能解除肿瘤微环境的免疫抑制，又能激活T细胞免疫应答。该研究将重点评估Opamtistomig在胃癌患者中的安全性和有效性，并为后续临床开发提供重要依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","BK1161","HK0000252152.HKD","HK0000252160.HKD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629089166","title":"维立志博-B(09887)：维利信TM(PD-L1/4-1BB双特异性抗体奥帕替苏米单抗，LBL-024)于一线胃或胃食管结合部腺癌II期试验的首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2629089166","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629089166?lang=zh_cn&edition=full","pubTime":"2026-04-21 16:46","pubTimestamp":1776761213,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)发布公告，评价维利信TM(PD-L1/4-1BB双特异性抗体奥帕替苏米单抗，LBL-024)用于治疗一线局部晚期或转移性胃或胃食管结合部腺癌的II期临床研究首例患者已成功入组。本次开展的开放标签、多中心Ⅱ期临床研究由北京大学肿瘤医院沈琳教授牵头，正在全国多家医院同步推进。该试验旨在评价奥帕替苏米单抗用于治疗一线局部晚期或转移性胃或胃食管结合部腺癌患者的有效性和安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431279.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4604","HK0000252160.HKD","BK4585","BK4588","BK4023","BK4555","LU1169589451.USD","03160","LU1169590202.USD","TM","09887","BK4099","HK0000500386.USD","HK0000252152.HKD","BK1161","PD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629086468","title":"东方证券：维持维立志博-B(09887)“买入”评级 目标价格为103.06港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629086468","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629086468?lang=zh_cn&edition=full","pubTime":"2026-04-21 15:22","pubTimestamp":1776756123,"startTime":"0","endTime":"0","summary":"东方证券主要观点如下：事件公司2025年实现营收1.8亿元，主要系LBL-047成功BD后收到的2500万美元首付及里程碑款项，助力公司营收端实现重大突破。临床进展顺利，LBL-024即将迎来出海关键窗口期截至3月底，LBL-024已在13个实体瘤适应症中推进9项临床研究，累计入组患者超600例。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431214.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["600958","09887","EWH","03958"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135825634","title":"异动解读 | 核心药物临床进展积极，维立志博-B盘中大涨6.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=1135825634","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135825634?lang=zh_cn&edition=full","pubTime":"2026-04-14 14:47","pubTimestamp":1776149255,"startTime":"0","endTime":"0","summary":"维立志博-B今日盘中股价大涨6.15%，引起了市场关注。消息面上，此次股价异动与公司核心在研产品LBL-024的临床研究进展密切相关。公司近日公告显示，LBL-024用于一线治疗晚期胆道癌的II期临床研究已完成安全性导入期评估，并顺利进入扩展阶段。初步数据显示，该药物联合化疗方案安全性与耐受性良好，且疗效数据呈现肿瘤缩小趋势，这为药物的后续开发提供了积极信号。此外，有券商报告指出，LBL-024的研发进展是公司当前的关键看点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627904574","title":"港股维立志博-B午后涨超6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627904574","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627904574?lang=zh_cn&edition=full","pubTime":"2026-04-14 14:42","pubTimestamp":1776148942,"startTime":"0","endTime":"0","summary":"4月14日，维立志博-B(09887.HK)午后涨超6%，截至发稿，涨6.15%，报94.95港元，成交额6329.96万港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604143704307322.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604143704307322.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","HK0000500386.USD","BK4585","HK0000252160.HKD","09887","HK0000252152.HKD","BK4588","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626971298","title":"港股维立志博-B涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2626971298","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626971298?lang=zh_cn&edition=full","pubTime":"2026-04-09 09:50","pubTimestamp":1775699417,"startTime":"0","endTime":"0","summary":"每经AI快讯，4月9日，维立志博-B(09887.HK)涨超4%，截至发稿涨4.39%，报93.9港元，成交额1337.78万港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604093699195647.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604093699195647.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["VXUS","09887","BK4588","HK0000252152.HKD","BK1161","HK0000500386.USD","HK0000252160.HKD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164229048","title":"异动解读 | 维立志博-B盘中大涨5.06%，维利信®胆道癌Ⅱ期研究进展顺利","url":"https://stock-news.laohu8.com/highlight/detail?id=1164229048","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164229048?lang=zh_cn&edition=full","pubTime":"2026-04-09 09:45","pubTimestamp":1775699106,"startTime":"0","endTime":"0","summary":"维立志博-B(09887)今日盘中大涨5.06%，引起了市场的广泛关注。消息面上，公司自主研发的PD-L1/4-1BB双特异性抗体维利信®（LBL-024）一线治疗晚期胆道癌的Ⅱ期临床研究已完成安全性导入期初步评估。基于良好的安全性和令人鼓舞的疗效数据，项目顺利进入扩展阶段，并已完成首例入组。数据显示，维利信®联合化疗整体安全性与耐受性良好，未发现新的安全性信号；初步的疗效评估显示的肿瘤缩小趋势令人振奋。这一积极进展增强了市场对公司未来在癌症治疗领域发展的信心，从而推动了股价的上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626605971","title":"港股异动 | 维立志博-B(09887)涨超4% 维利信®一线治疗胆道癌Ⅱ期研究顺利进入扩展阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2626605971","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626605971?lang=zh_cn&edition=full","pubTime":"2026-04-09 09:41","pubTimestamp":1775698874,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维立志博-B(09887)涨超4%，截至发稿，涨4.39%，报93.9港元，成交额1337.78万港元。消息面上，4月8日，维立志博宣布，公司自主研发的PD-L1/4-1BB双特异性抗体维利信®（LBL-024）一线治疗晚期胆道癌的Ⅱ期临床研究已完成安全性导入期初步评估。基于良好的安全性和令人鼓舞的疗效数据，项目顺利进入扩展阶段，并已完成首例入组。数据显示，维利信®联合化疗整体安全性与耐受性良好，未发现新的安全性信号；初步的疗效评估显示的肿瘤缩小趋势令人振奋。基于良好的安全性与令人鼓舞的疗效数据，项目顺利进入扩展阶段并加速推进。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426345.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252160.HKD","HK0000252152.HKD","BK4588","HK0000500386.USD","09887","BK4585","VXUS","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625117919","title":"维立志博-B(09887)：维利信TM治疗胆道癌II期研究顺利进入扩展阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2625117919","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625117919?lang=zh_cn&edition=full","pubTime":"2026-04-08 16:34","pubTimestamp":1775637275,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)公布，评价维利信TM(PD-L1/4-1BB双特异性抗体奥帕替苏米单抗，LBL-024)用于一线治疗晚期胆道癌的Ⅱ期临床研究已完成安全性导入期初步评估。基于良好的安全性和令人鼓舞的初步疗效数据，该研究已顺利进入扩展阶段，并已完成首例患者入组。该研究由复旦大学附属中山医院周俭院士牵头，正在全国多家医院同步推进。在安全性导入期，共计20例受试者完成初步评估。数据显示维利信TM联合化疗整体安全性与耐受性良好，未发现新的安全性信号。初步的疗效数据亦显示肿瘤缩小趋势令人振奋。基于良好的安全性与令人鼓舞的疗效数据，该研究进入扩展阶段并加速推进。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425966.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03160","BK4099","09887","BK4588","BK4585","HK0000252160.HKD","HK0000252152.HKD","BK4604","BK4555","TM","BK1161","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183124933","title":"异动解读 | 维立志博-B(09887)盘中大涨13.24%，因两项临床前研究成果获选AACR年会展示","url":"https://stock-news.laohu8.com/highlight/detail?id=1183124933","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183124933?lang=zh_cn&edition=full","pubTime":"2026-04-01 12:30","pubTimestamp":1775017825,"startTime":"0","endTime":"0","summary":"维立志博-B(09887)今日盘中股价大幅上涨13.24%，引起了市场的高度关注。消息面上，公司发布公告，宣布其两项临床前管线研究成果将在2026年美国癌症研究协会(AACR)年会上进行展示。这两项研究分别展示了公司在细胞衔接器-药物偶联物及双靶点ADC领域的创新进展，进一步验证了其LeadsBody、X-body及TOPiKinectics三大核心专有技术平台的协同研发战略与潜力。此次研究成果入选国际顶级癌症研究会议，被视为公司研发实力的重要体现，增强了投资者对其未来产品管线价值和长期增长前景的信心，从而推动了股价的显著上扬。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.leadsbiolabs.com","stockEarnings":[{"period":"1week","weight":-0.2128},{"period":"1month","weight":-0.3246},{"period":"3month","weight":0.0342},{"period":"6month","weight":0.0754},{"period":"1year","weight":0.8129},{"period":"ytd","weight":0.2441}],"compareEarnings":[{"period":"1week","weight":-0.0163},{"period":"1month","weight":0.0006},{"period":"3month","weight":-0.0227},{"period":"6month","weight":-0.041},{"period":"1year","weight":0.107},{"period":"ytd","weight":0.013}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"南京维立志博生物科技股份有限公司是一家主要从事发现、开发和商业化治疗肿瘤、自身免疫性疾病以及其他严重疾病的新疗法的中国公司。该公司的主要候选药物包括LBL-024、LBL-034、LBL-033、LBL-007等。该公司的LBL-024主要用于治疗肺外神经内分泌癌（EP-NEC）、小细胞肺癌（SCLC）、胆道癌（BTC）及非小细胞肺癌（NSCLC）、食管鳞状细胞癌（ESCC）、肝细胞癌（HCC）、胃癌（GC）及其他实体瘤。该公司还开发了专有技术平台，包括LeadsBody平台（CD3 T-cell engager平台）、X-body平台（4-1BB engager平台）以及其他几个双特异性抗体及融合蛋白平台。该公司主要在国内市场开展业务。","exchange":"SEHK","name":"维立志博-B","nameEN":"LEADS BIOLABS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"维立志博-B(09887)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供维立志博-B(09887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"维立志博-B,09887,维立志博-B股票,维立志博-B股票老虎,维立志博-B股票老虎国际,维立志博-B行情,维立志博-B股票行情,维立志博-B股价,维立志博-B股市,维立志博-B股票价格,维立志博-B股票交易,维立志博-B股票购买,维立志博-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"维立志博-B(09887)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供维立志博-B(09887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}